

## 2018 Financial Report

The International Kidney Cancer Coalition continues to grow in reach and impact with many shared accomplishments. IKCC remains in a healthy financial position to ensure delivery of all our projects and programs consistent with our mission and vision.

We commenced 2018 in a strong financial position with a surplus of €104,788. Throughout 2018 we continued to be well supported in our work through our Sustaining Partners and Sponsors - without their support we could not develop or implement our work and projects as outlined in our Activity Report available here: <https://ikcc.org/about-ikcc/annual-reports/>

At the end of 2018 we posted an increase in our net working capital of €231,771 finishing with an accumulated funds total of €425,709. This total includes pre-payments towards 2019 projects, and 12 months operating reserves as part of the IKCC financial sustainability policy.

Following transition of management of IKCC to the Netherlands, we have been working to bring new accountants and Auditors on board to take over official auditing of IKCC accounts going forward. As a result of timing of the transition to new Auditors, a full and complete audit of the 2018 financial statements could not be finalised.

Nonetheless, the financial statements presented in the 2018 Activity Report have been reviewed by IKCC's new Audit Partners Flanq Accountants & Adviseurs and represent a true and accurate record of the IKCC financial position.

These statements have been reviewed and accepted by the IKCC Board.

Signed:



Dr. Rachel Giles  
IKCC Chair



Anne Wilson  
Secretary/Treasurer

Date: 31.07.2019

Date: 31.07.2019

**IKCC**  
**Board Members**  
**Mgmt. Services**  
**Legal Entity**

The Global Collaboration Of National Patient Groups Supporting Those Affected By Kidney Cancer.  
R. Giles (NL) \* D. Maskens (CA) \* B. Eberhardt (DE) \* M. Jewett (CA) \*  
E. Jonasch (USA) \* B. Lewis (USA) \* L. Perdeaux (UK) \* A. Wilson (AU) \* R. Woodward (UK)  
Julia Black (UK) [julia@ikcc.org](mailto:julia@ikcc.org)  
Foundation, registered in the Netherlands: Stichting Intl. Kidney Cancer Coalition, Reg.No. KvK 62070665

## **IKCC International Kidney Cancer Coalition**

*A global collaboration of patient organisations that empowers and represents the kidney cancer community through advocacy, awareness, information and research.*

### **IKCC Board**

Dr Rachel Giles, Chair (NL)  
Deborah Maskens, Vice Chair (CA)  
Berit Eberhardt (DE)  
Dr Michael A.S. Jewett (CA)  
Dr Eric Jonasch (USA)  
Bryan Lewis (USA)  
Elizabeth Perdeaux (UK)  
Anne Wilson (AU)  
Rose Woodward (UK)

### **Medical Advisory Board:**

Dr Michael A.S. Jewett, Chair (CA)  
Dr Eric Jonasch, Vice Chair (USA)  
Dr Axel Bex (NL/UK)  
Dr Daniel Heng (CA)  
Prof. James Larkin (UK)

### **Auditor:**

FlanQ, Accountants & Adviseurs  
Jan Valsterweg 87, 3315 LG Dordrecht; Netherlands

### **Financial Services:**

Administratiekantoor Boekjewinst.nl BV,  
Computerweg 22, 3542DR Utrecht, The Netherlands

### **Registered Address:**

Stichting IKCC  
't Ven 30  
1115HB Duivendrecht, The Netherlands

### **IKCC Board Members Mgmt. Services Legal Entity**

The Global Collaboration Of National Patient Groups Supporting Those Affected By Kidney Cancer.  
R. Giles (NL) \* D. Maskens (CA) \* B. Eberhardt (DE) \* M. Jewett (CA) \*  
E. Jonasch (USA) \* B. Lewis (USA) \* L. Perdeaux (UK) \* A. Wilson (AU) \* R. Woodward (UK)  
Julia Black (UK) [julia@ikcc.org](mailto:julia@ikcc.org)  
Foundation, registered in the Netherlands: Stichting Intl. Kidney Cancer Coalition, Reg.No. KvK 62070665

To:

The board of Stichting International Kidney Cancer Coalition  
't Ven 30  
1115 HB Duivendrecht  
The Netherlands

We have reviewed the financial statements 2018 of Stichting International Kidney Cancer Coalition at Duivendrecht, that comprise the balance sheet as at 31 December 2018, the profit and loss account for the year then ended and the notes, comprising a summary of the accounting policies and other explanatory information.

#### **Management's responsibility**

The board is responsible for the preparation and fair presentation of the financial statements in accordance with Part 9 of Book 2 of the Dutch Civil Code and RJ 650 fondsenwervende organisaties of the Dutch Council for financial reporting. Furthermore management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

#### **Accountant's responsibility**

Our responsibility is to express a conclusion on the financial statements. We conducted our review in accordance with Dutch law, including the Dutch Standard 2400 'Engagements to Review Financial Statements'. This requires that we comply with ethical requirements and that we plan and perform the review to be able to conclude whether anything has come to our attention that causes us to believe that the financial statements are not prepared in all material respects in accordance with the applicable financial reporting framework.

A review of financial statements in accordance with the Dutch Standard 2400 is a limited assurance engagement. The performed procedures consisted primarily of making inquiries of management and others within the entity, as appropriate, applying analytical procedures and evaluating the evidence obtained.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with the Dutch Standards on Auditing. Accordingly, we do not express an audit opinion.

Jan Valsterweg 87  
3315 LG Dordrecht  
Tel. 078 - 622 90 90

Trasmolen 53  
3146 TE Maassluis  
Tel. 010 - 591 91 93

[info@FlanQ.nl](mailto:info@FlanQ.nl)  
[www.FlanQ.nl](http://www.FlanQ.nl)

KvK nr. 64701395  
BTW nr. 855788069B01  
NL09 ABNA 0480 2196 56  
NL06 INGB 0007 9960 10

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the financial statements do not give a true and fair view of the financial position of Stichting International Kidney Cancer Coalition as at 31 December 2018 and of its result for 2018 the year then ended in accordance with Part 9 of Book 2 of the Dutch Civil Code.

**Unaudited and unreviewed corresponding figures**

We have not audited or reviewed the financial statements 2017. Consequently, we have not audited or reviewed the corresponding figures included in the profit and loss account, in the statements of changes and in the related notes.

Dordrecht, 14 March 2019

FlanQ Accountants & Adviseurs

Dordrecht

F. van Lonkhuizen AA

# **Annual Accounts 2018**

**Stichting International Kidney Cancer Coalition  
't Ven 30  
1115 HB Duivendrecht**

**TABLE OF CONTENTS****PAGE****ACCOUNTANTS REPORT**

1	General	2
2	Financial position	3

**ANNUAL ACCOUNTS**

1	Balance sheet as at 31 December 2018	5
2	Statement of income and expenditure	6
3	Cash-flow statement 2018	7
4	Notes on the balance sheet as at 31 December 2018	10
5	Notes on the statement of income and expenditure for 2018	13

# **ACCOUNTANTS REPORT**

To the Board of  
Stichting International Kidney Cancer Coalition  
't Ven 30  
1115 HB Duivendrecht

Dear Management,

We hereby issue a report on the 2018 financial year with regard to the foundation.

## **1 GENERAL**

### **1.1 Company information**

The International Kidney Cancer Coalition (IKCC) is an independent international network of patient organisations that focus exclusively, or include a specific focus, on kidney cancer. It is legally incorporated as a Foundation in the Netherlands. The organisation was born from a very strong desire among various national kidney cancer patient groups to network, cooperate and share materials, knowledge, and experiences. IKCC is governed by a volunteer Board of Directors with members from a minimum of four countries.

### **1.2 Board of directors**

The board of the International Kidney Cancer Coalition Foundation consists of:

Dr R. Giles - Board Chair  
Ms D. A. Maskens - Board vice-Chair  
Ms A. C. R. Wilson - Secretary / Treasurer  
Ms R.A. Woodward - Board Member  
Dr M. Jewett - Board Member  
Mr. B. Lewis - Board Member  
Ms B. K. Eberhardt-Wetherington - Board Member  
Dr E. Perdeaux - Board Member  
Dr E. Jonasch - Board Member



**2 FINANCIAL POSITION**

The financing structure below is derived from the balance sheet:

	31-12-2018		31-12-2017	
	€	€	€	€
<b>Available in the long term:</b>				
Reserves		425.709		194.463
<b>Of which fixed in the long term:</b>				
Tangible fixed assets		-		525
Working capital		<u>425.709</u>		<u>193.938</u>

This amount has been used as follows:

Accounts receivable	1.216		49.267	
Liquid assets	<u>524.877</u>		<u>254.814</u>	
		526.093		304.081
Less: short-term debts		100.384		110.143
Working capital		<u>425.709</u>		<u>193.938</u>

**2.1 Notes**

According to this arrangement, the working capital at 31 December 2018 compared to 31 December 2017 has increased by € 231,771.

## **Annual accounts**

**1 BALANCE SHEET AS AT 31 DECEMBER 2018**

(after appropriation of the result)

	31 December 2018		31 December 2017	
	€	€	€	€
<b>ACTIVE</b>				
<b>Fixed assets</b>				
Tangible fixed assets	(1)	-		525
<b>Current assets</b>				
<b>Accounts receivable</b>				
Other receivables and accruals assets	(2)	1.216		49.267
<b>Liquid assets</b>	(3)	524.877		254.814
		<u>526.093</u>		<u>304.606</u>
<b>PASSIVE</b>				
<b>Foundation's capital</b>				
Free reserves	(4)	425.709		194.463
<b>Current liabilities</b>				
Debts to suppliers and commercial credits	(5)	1.339		14.846
Other debts and deferred income		99.045		95.297
		<u>100.384</u>		<u>110.143</u>
		<u>526.093</u>		<u>304.606</u>

**2 STATEMENT OF INCOME AND EXPENDITURE**

		2018		2017	
		€	€	€	€
<b>Income</b>	(6)	701.657		536.022	
Expenditure	(7)	<u>469.886</u>		<u>431.234</u>	
<b>Operating surplus</b>			231.771		104.788
Depreciations of fixed tangible assets	(8)		525		-
			-		-
<b>Surplus</b>			<u>231.246</u>		<u>104.788</u>

**3 CASH-FLOW STATEMENT 2018**

The cash flow statement has been prepared pursuant to the indirect method.

	2018	
	€	€
<b>Cashflow from operating activities</b>		
Operating result	231.246	
Adjustments for:		
Depreciations	525	
Changes in working capital:		
Transfers in receivables	48.051	
Transfer in short-term debts (excluding the current part of the long-term debts)	-9.759	
Cashflow from business operations		270.063
Cashflow from operating activities		270.063
		270.063

**Composition of cash**

	2018	
	€	€
Cash as at 1 January		254.814
Cash movements		270.063
Cash as at 31 December		524.877

### **Established address**

Stichting International Kidney Cancer Coalition (registered under Chamber of Commerce number 62070665) is physically located at 't Ven 30 in Duivendrecht.

### **GENERAL ACCOUNTING PRINCIPLES FOR THE PREPARATION OF THE ANNUAL ACCOUNTS**

The annual accounts have been prepared in accordance with directive 640 (small non-profit organisations) model RjK CI of the Annual Reporting Council.

The valuation of assets and liabilities and the determination of the result are based on historical costs. Unless stated otherwise in the respective basis for the specific balance sheet item, the assets and liabilities are valued according to the cost-price model.

Income and expenditure are allocated to the year to which they are related. Profits are only included to the extent they have been achieved on the balance sheet date. Liabilities and potential losses originating before the end of the reporting year are taken into account if they are known before the preparation of the annual accounts.

### **PRINCIPLES FOR THE VALUATION OF ASSETS AND LIABILITIES**

#### **Tangible fixed assets**

The tangible fixed assets are valued at the acquisition price less cumulative depreciations and, where applicable, with special impairments. The depreciations are based on the estimated economic lifecycle and is calculated on the basis of a fixed percentage of the acquisition price, while allowing for any residual value. Depreciation takes place from the moment the item has come into service.

#### **Receivables and prepayments and accrued income**

The receivables are initially recognised at fair value and subsequently valued at amortised cost. The fair value and amortised cost are equal to the nominal value. Provisions deemed necessary for the risk of bad debts are deducted. These provisions are determined based on individual assessment of the receivables.

#### **Liquid assets**

The cash and cash equivalents are valued at nominal value. If funds are not freely available, this is taken into account in the valuation.

### **Current liabilities**

Short-term debts are initially measured at fair value. After initial recognition, short-term debts are valued at amortised cost.

Where there are no (discount) premium and transaction charges, the amortised cost is equal to the nominal value.

### **PRINCIPLES FOR DETERMINATION OF RESULT**

#### **General**

The operating result is determined as the difference between the income on the one hand and on the other hand the direct and other expenses of the year, valued at historical cost.

A surplus must be used, in accordance with what has been agreed, for future activities of the foundation.

#### **Income**

Income means the income from the funds and related fees received in the year under review.

#### **Expenditure**

The direct costs comprise the charges that can be directly attributed to the objectives set by Stichting International Kidney Cancer Coalition.

### **PRINCIPLES FOR THE PREPARATION OF THE CASH-FLOW STATEMENT**

The cash-flow statement has been prepared according to the indirect method.

The cash in the cash-flow statement consists of cash, short-term debts to credit institutions and the current securities.

The securities can be considered as highly liquid investments.

Cash flows in foreign currencies have been converted at an estimated average rate. Exchange-rate differences with regard to cash are shown separately in the cash-flow statement.

**4 NOTES ON THE BALANCE SHEET AS AT 31 DECEMBER 2018****ACTIVE****FIXED ASSETS**

	<u>31-12-2018</u>	<u>31-12-2017</u>
	€	€
<b>1. Tangible fixed assets</b>		
Inventory	-	<u>525</u>

	<u>Inventory</u>
	€
<i>Balance-sheet value as at 1 January 2018</i>	
Purchasing value	525
Cumulative depreciations and value reductions	-
	<u>525</u>
Depreciations	<u>-525</u>
<i>Balance-sheet value as at 31 December 2018</i>	
Purchasing value	525
Cumulative depreciations and value reductions	-525
Balance-sheet value as at 31 December 2018	<u>-</u>

*Depreciation percentages*

	%
Inventory	100



**CURRENT ASSETS****2. Accounts receivable**

	<u>31-12-2018</u>	<u>31-12-2017</u>
	€	€
<b>Prepayments and accrued income</b>		
Amounts receivable	1.216	-
Prepaid amounts	-	49.267
	<u>1.216</u>	<u>49.267</u>

**3. Liquid assets**

ING Bank payment account	2.217	104.814
ING Bank reserve operating account	150.063	150.000
ING Bank US Dollar account	146.597	-
ING Bank saving account	226.000	-
	<u>524.877</u>	<u>254.814</u>

**PASSIVE**

	<u>31-12-2018</u>	<u>31-12-2017</u>
	€	€
<b>4. Foundation's capital</b>		
Free reserves	<u>425.709</u>	<u>194.463</u>
	<u>2018</u>	<u>2017</u>
	€	€
<b>Free reserves</b>		
Balance sheet as at 1 January	194.463	89.675
Result appropriation for the balance-sheet year	<u>231.246</u>	<u>104.788</u>
Balance as at 31 December	<u>425.709</u>	<u>194.463</u>
<b>5. Current liabilities</b>		
	<u>31-12-2018</u>	<u>31-12-2017</u>
	€	€
<b>Debts to suppliers and commercial credits</b>		
Creditors	<u>1.339</u>	<u>14.846</u>
<b>Deferred and accrued liabilities</b>		
Amounts received in advance	90.435	-
Payable costs	<u>8.610</u>	<u>95.297</u>
	<u>99.045</u>	<u>95.297</u>

5 **NOTES ON THE STATEMENT OF INCOME AND EXPENDITURE FOR 2018**

	<u>2018</u>	<u>2017</u>
	€	€
<b>6. Income</b>		
Sustaining partnerships	171.941	305.731
Projects	<u>529.716</u>	<u>230.291</u>
	<u>701.657</u>	<u>536.022</u>
<b>7. Expenditure</b>		
Objective 1: To strengthen the capacity of current and emerging affiliates in their support for patients with Kidney Cancer	131.290	87.248
Objective 2: To advocate for access to best care	77.247	5.789
Objective 3: To increase awareness of Kidney Cancer globally	155.866	118.818
Objective 4: To be an authority in the provision of Kidney Cancer information	59.220	110.400
Objective 5: To foster projects promoting the voice of Kidney Cancer patients in research activities worldwide	<u>46.263</u>	<u>108.979</u>
	<u>469.886</u>	<u>431.234</u>
<b>Depreciations</b>		
<b>8. Depreciations of fixed tangible assets</b>		
Inventory	<u>525</u>	<u>-</u>